8-K: Avanos Medical Announces Separation and Consulting Agreement with Michael C. Greiner

Avanos Medical, Inc. finalizes separation agreement with Michael C. Greiner, including severance, bonus, benefits, and a short-term consulting role.

Summary

• Avanos Medical, Inc. and Michael C. Greiner entered into a Separation and Consulting Agreement on April 28, 2025.
• Mr. Greiner's departure was previously disclosed on April 18, 2025.
• Avanos will pay Mr. Greiner $2,100,000 in cash severance.
• He will also receive a prorated bonus for 2025, paid in 2026.
• The company will cover 100% of Mr. Greiner's monthly COBRA premiums for six months.
• 44,189 time-based restricted stock units (TRSUs) granted on October 29, 2024, and 10,000 TRSUs granted on December 3, 2024, will vest immediately.
• Mr. Greiner will serve as an independent contractor through May 16, 2025, for which he will be paid $50,000.
• A Full and Final Release of Claims and Covenant Not to Sue was also executed.
• Payments and benefits are contingent upon Mr. Greiner's non-revocation of the Release, execution of a supplemental release, and compliance with his Confidentiality Agreement.

Sentiment

Score: 6

Explanation: The document is neutral in tone, detailing the terms of an executive separation agreement. While executive departures can sometimes be viewed negatively, the consulting arrangement suggests a focus on continuity.

Positives

• The agreement provides clarity and resolution regarding Mr. Greiner's departure.
• The company secures a release of claims from Mr. Greiner, minimizing potential legal risks.
• A short-term consulting arrangement allows for a smooth transition and continued access to Mr. Greiner's expertise.

Negatives

• The company incurs significant severance and benefit costs related to Mr. Greiner's departure.
• Immediate vesting of restricted stock units could dilute shareholder value.

Risks

• Failure to comply with Section 409A of the Internal Revenue Code could result in tax penalties.
• Mr. Greiner's breach of the Confidentiality Agreement could harm the company.
• There is a risk that Mr. Greiner could revoke the Release agreement.

Future Outlook

The company anticipates a smooth transition with Mr. Greiner's consulting services, while also mitigating future legal risks through the release agreements.

Industry Context

Executive departures and transitions are common in the medical device industry. Companies often utilize consulting agreements to ensure continuity and knowledge transfer during these periods.

Comparison to Industry Standards

• Severance packages for executives in the medical device industry typically include cash severance, bonus payments, benefits continuation, and accelerated vesting of equity awards.
• Consulting agreements are frequently used to retain expertise and ensure a smooth transition after an executive's departure.
• The specific terms of the agreement, such as the severance amount and consulting fees, are likely based on Mr. Greiner's role, tenure, and contributions to the company.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the costs associated with the executive departure.
• Employees may experience uncertainty during the transition period.
• Customers and suppliers are unlikely to be directly impacted by this change.

Next Steps

• Mr. Greiner will provide consulting services through May 16, 2025.
• The company will pay Mr. Greiner's severance and benefits as outlined in the agreement.
• Mr. Greiner must execute a Supplemental Release on (but not before) the Consulting Termination Date or within seven (7) days after the Consulting Termination Date.

Key Dates

Keywords

Separation Agreement, Consulting Agreement, Severance, Restricted Stock Units, COBRA, Release of Claims, Avanos Medical, Michael Greiner, Executive Departure